Literature DB >> 22820548

GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation.

Maria Negahdar1, Ingvild Aukrust, Bente B Johansson, Janne Molnes, Anders Molven, Franz M Matschinsky, Oddmund Søvik, Rohit N Kulkarni, Torgeir Flatmark, Pål Rasmus Njølstad, Lise Bjørkhaug.   

Abstract

GCK-MODY, dominantly inherited mild fasting hyperglycemia, has been associated with >600 different mutations in the glucokinase (GK)-encoding gene (GCK). When expressed as recombinant pancreatic proteins, some mutations result in enzymes with normal/near-normal catalytic properties. The molecular mechanism(s) of GCK-MODY due to these mutations has remained elusive. Here, we aimed to explore the molecular mechanisms for two such catalytically 'normal' GCK mutations (S263P and G264S) in the F260-L270 loop of GK. When stably overexpressed in HEK293 cells and MIN6 β-cells, the S263P- and G264S-encoded mutations generated misfolded proteins with an increased rate of degradation (S263P>G264S) by the protein quality control machinery, and a propensity to self-associate (G264S>S263P) and form dimers (SDS resistant) and aggregates (partly Triton X-100 insoluble), as determined by pulse-chase experiments and subcellular fractionation. Thus, the GCK-MODY mutations S263P and G264S lead to protein misfolding causing destabilization, cellular dimerization/aggregation and enhanced rate of degradation. In silico predicted conformational changes of the F260-L270 loop structure are considered to mediate the dimerization of both mutant proteins by a domain swapping mechanism. Thus, similar properties may represent the molecular mechanisms for additional unexplained GCK-MODY mutations, and may also contribute to the disease mechanism in other previously characterized GCK-MODY inactivating mutations.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820548      PMCID: PMC3444650          DOI: 10.1016/j.bbadis.2012.07.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  62 in total

1.  Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused.

Authors:  R B Kapust; D S Waugh
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

2.  Cell-biological assessment of human glucokinase mutants causing maturity-onset diabetes of the young type 2 (MODY-2) or glucokinase-linked hyperinsulinaemia (GK-HI).

Authors:  C V Burke; C W Buettger; E A Davis; S J McClane; F M Matschinsky; S E Raper
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

3.  Familial hyperinsulinism caused by an activating glucokinase mutation.

Authors:  B Glaser; P Kesavan; M Heyman; E Davis; A Cuesta; A Buchs; C A Stanley; P S Thornton; M A Permutt; F M Matschinsky; K C Herold
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

Review 4.  Probing the partly folded states of proteins by limited proteolysis.

Authors:  A Fontana; P Polverino de Laureto; V De Filippis; E Scaramella; M Zambonin
Journal:  Fold Des       Date:  1997

5.  Co-localization of glucokinase with actin filaments.

Authors:  T Murata; H Katagiri; H Ishihara; Y Shibasaki; T Asano; Y Toyoda; B Pekiner; C Pekiner; I Miwa; Y Oka
Journal:  FEBS Lett       Date:  1997-04-07       Impact factor: 4.124

6.  Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype.

Authors:  S P Miller; G R Anand; E J Karschnia; G I Bell; D C LaPorte; A J Lange
Journal:  Diabetes       Date:  1999-08       Impact factor: 9.461

7.  Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis.

Authors:  E A Davis; A Cuesta-Muñoz; M Raoul; C Buettger; I Sweet; M Moates; M A Magnuson; F M Matschinsky
Journal:  Diabetologia       Date:  1999-10       Impact factor: 10.122

8.  Structural instability of mutant beta-cell glucokinase: implications for the molecular pathogenesis of maturity-onset diabetes of the young (type-2).

Authors:  P Kesavan; L Wang; E Davis; A Cuesta; I Sweet; K Niswender; M A Magnuson; F M Matschinsky
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

9.  Variable effects of maturity-onset-diabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme.

Authors:  Y Liang; P Kesavan; L Q Wang; K Niswender; Y Tanizawa; M A Permutt; M A Magnuson; F M Matschinsky
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

10.  Nuclear location of the regulatory protein of glucokinase in rat liver and translocation of the regulator to the cytoplasm in response to high glucose.

Authors:  Y Toyoda; I Miwa; S Satake; M Anai; Y Oka
Journal:  Biochem Biophys Res Commun       Date:  1995-10-13       Impact factor: 3.575

View more
  4 in total

1.  Case 6-2020: A 34-Year-Old Woman with Hyperglycemia.

Authors:  Miriam S Udler; Camille E Powe; Christina A Austin-Tse
Journal:  N Engl J Med       Date:  2020-02-20       Impact factor: 91.245

2.  SUMOylation of pancreatic glucokinase regulates its cellular stability and activity.

Authors:  Ingvild Aukrust; Lise Bjørkhaug; Maria Negahdar; Janne Molnes; Bente B Johansson; Yvonne Müller; Wilhelm Haas; Steven P Gygi; Oddmund Søvik; Torgeir Flatmark; Rohit N Kulkarni; Pål R Njølstad
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

Review 3.  The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY).

Authors:  Ken Munene Nkonge; Dennis Karani Nkonge; Teresa Njeri Nkonge
Journal:  Clin Diabetes Endocrinol       Date:  2020-11-04

4.  Identification of the ubiquitin-like domain of midnolin as a new glucokinase interaction partner.

Authors:  Anke Hofmeister-Brix; Katrin Kollmann; Sara Langer; Julia Schultz; Sigurd Lenzen; Simone Baltrusch
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.